ArticleHIV medicine2022
Impact of COVID-19 on HIV late diagnosis in a specialized German centre.
Article in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Characteristics of late HIV diagnosis in Germany in 2019 and 2020 - A regional analysis.Infection · 2026Article
- Changes in Care and Outcome for Children and Adolescents Living With HIV/AIDS During the COVID19 Pandemic in Germany-A Longitudinal Study.Health science reports · 2026Article
- Clinical presentation and effectiveness of antiretroviral therapy in newly diagnosed people living with HIV before, during and after the COVID-19 pandemic.BMJ public health · 2026Article
- Assessing the impact of COVID-19 on HIV and hepatitis B testing in Western Iran: insights from an interrupted time series analysis.BMC public health · 2025Article
- Control of HIV across the WHO European region: progress and remaining challenges.The Lancet regional health. Europe · 2025Review
- The impact of the COVID-19 pandemic on HIV testing in Peru: an interrupted time series analysis from 2014 to 2022.BMC infectious diseases · 2025Article
- Impact of the COVID-19 Pandemic on the Clinical Management of People Living with HIV: A Retrospective Study of 246 Patients at a Single Center.Current HIV research · 2025Article
- Recruitment for Voluntary Video and Mobile HIV Testing on Social Media Platforms During the COVID-19 Pandemic: Cross-Sectional Study.Journal of medical Internet research · 2024Article
- Article
- Determinants of HIV late presentation among men who have sex with men in Portugal (2014-2019): who's being left behind?Frontiers in public health · 2024Article
- Prevalence, characteristics and challenges of late HIV diagnosis in Germany: an expert narrative review.Infection · 2023Review
- Interviews with HIV Experts for Development of a Mobile Health Application in HIV Care-A Qualitative Study.Healthcare (Basel, Switzerland) · 2023Article
- Late Diagnosis in HIV with New and Old Definitions; Data from a Regional Hospital in Turkey.International journal of general medicine · 2023Article
- Impact of COVID-19 on HIV late diagnosis in a specialized German centre.HIV medicine · 2022Article
- Evolving Trends in Late HIV Diagnosis: Increasing Frequency but Improved Survival and Reduced Opportunistic Infections in a 10-Year Hospital-Based Cohort.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ongoing COVID-19 pandemic has been impeding HIV diagnosis and treatment worldwide. Data on the impact of COVID-19 on late diagnosis (LD) in Germany are lacking. Here we present novel data of a single-centre German HIV cohort assessing LD during COVID-19.
methodsThis is a non-interventional, single-centre retrospective cohort assessing the rate of LD comparing HIV diagnoses pre-COVID-19 with those during the COVID-19 pandemic. New diagnoses between 1 January 2019 and 1 February 2020 were classified as pre-COVID-19, and diagnoses between 1 February 2020 and 1 October 2021 were classified as during COVID-19.
resultsBetween 1 January 2019 and 1 October 2021, 75 patients presented with newly diagnosed HIV infection, 34 pre-COVID-19 and 41 during COVID-19. LD increased to 83% (n = 34/41) during COVID-19 versus 59% (n = 20/34) pre-COVID-19, and CDC stage C3 rose to 44% (n = 18) versus 27%. Hospitalization rate increased to 49% (n = 20) during COVID-19 versus 29% pre-COVID-19, and 12% (n = 5) presented with HIV-associated neurological disease, whereas none were observed in the pre-COVID-19 group. The incidence of LD (p = 0.020), CD4 count < 350 cells/μL (p = 0.037) and < 200 cells/μL (p = 0.022) were statistically significantly associated with the ongoing COVID-pandemic. An association with HIV transmission risk was borderline significant (p = 0.055).
conclusionsDespite comparable annual rates of new HIV diagnoses, LD has been increasing during the COVID-19 pandemic, resulting in more opportunistic infections and higher hospitalization rates, possibly reflecting pandemic-related shortages in HIV testing and care facilities. Maintaining HIV testing opportunities and access to treatment during a pandemic is crucial so as not to impede WHO elimination goals and so as to prevent an increase in AIDS-related morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.